미생물학 및 세균 배양 배지 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 지역별, 부문별 예측(2025-2030년)

Microbiology & Bacterial Culture Media Market Growth & Trends:

The global microbiology & bacterial culture media market size is estimated at USD 9.01 billion in 2030 and is expected to grow at a CAGR of 8.82% over the forecast period, according to a new report by Grand View Research, Inc. The microbiology and bacterial culture media market is driven primarily by the rising prevalence of infectious diseases and antimicrobial resistance (AMR) across the globe. The growing burden of diseases such as tuberculosis, pneumonia, and foodborne illnesses has increased the demand for accurate and rapid microbial testing, boosting the use of high-quality culture media in clinical laboratories.

The COVID-19 pandemic further highlighted the importance of robust diagnostic infrastructure, prompting increased investment in microbiological testing facilities and technologies. Moreover, ongoing public health surveillance efforts and the emergence of new pathogens continue to sustain demand for standardized, reliable culture media across healthcare settings.

Another major driver is the growing focus on food safety, pharmaceutical quality assurance, and environmental monitoring. Regulatory bodies such as the FDA, EMA, and WHO have established strict guidelines for microbial testing in drug production, food processing, and water quality management, driving manufacturers to adopt sophisticated bacterial culture media. Industries are increasingly using ready-to-use (RTU) and chromogenic media to streamline workflows, reduce contamination risks, and comply with global quality standards. The integration of automation in industrial microbiology further enhances the utility of pre-prepared media, especially in high-throughput testing environments.

Lastly, technological advancements and increased R&D activity have significantly enhanced the capabilities of culture media products. Innovations such as chromogenic and fluorogenic media, along with media tailored for specific microbial strains or resistance markers, enable faster and more accurate identification. Coupled with digital and AI-driven diagnostic platforms, these innovations improve laboratory efficiency and outcomes. In addition, growing investments in biotechnology, personalized medicine, and vaccine development are fueling demand for specialized culture media in research settings. The expansion of healthcare infrastructure in emerging markets also contributes to market growth, offering manufacturers new opportunities for regional penetration and customized product offerings.

Microbiology & Bacterial Culture Media Market Report Highlights:

• By product, the dehydrated culture media segment dominated the market with a 56.84% share in 2024. The market for Dehydrated Culture Media (DCM) is driven by its long shelf life, ease of storage, and cost-effectiveness, making it an ideal choice for laboratories, pharmaceutical companies, and food safety testing facilities.
• By application, the pharmaceutical & biotechnology companies segment dominated the market and accounted for the largest revenue share in 2024. The market is strongly driven by increasing demand in pharmaceutical and biopharmaceutical manufacturing, where microbial culture is essential for the development, production, and quality assurance of products like antibiotics, vaccines, biologics, and probiotics.
• North America held the largest share of 37.8% in 2024. The market is driven by the growing incidence of infectious diseases, especially antibiotic-resistant strains, which underscores the need for rapid and precise diagnostic solutions. In addition, strict regulatory standards in food and pharmaceutical safety are amplifying the demand for reliable microbial testing methods.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Microbiology & Bacterial Culture Media Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growth in global food microbiology testing
    • 3.2.1.2. Rising need for high-quality culture media for diagnostic applications
    • 3.2.1.3. Continuous advancements in biopharmaceutical manufacturing
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of advanced or specialty media
    • 3.2.2.2. Growing preference for alternative methods like molecular diagnostics
• 3.3. Microbiology & bacterial culture media market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Microbiology & Bacterial Culture Media Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Global Microbiology & Bacterial Culture Media Market Product Movement Analysis
• 4.3. Global Microbiology & Bacterial Culture Media Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Dehydrated Culture Media
  • 4.4.1. Dehydrated Culture Media Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
• 4.5. Ready-to-use Media
  • 4.5.1. Ready-to-use Media Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)

Chapter 5. Microbiology & Bacterial Culture Media Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Microbiology & Bacterial Culture Media Market Application Movement Analysis
• 5.3. Global Microbiology & Bacterial Culture Media Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Pharmaceutical & Biopharmaceutical Production
  • 5.4.1. Pharmaceutical & Biopharmaceutical Production Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 5.5. Diagnostics
  • 5.5.1. Diagnostics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 5.6. Food & Water Testing
  • 5.6.1. Food & Water Testing Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 5.6.2. Food
    • 5.6.2.1. Food Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 5.6.3. Animal Feed
    • 5.6.3.1. Animal Feed Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 5.6.4. Water Testing
    • 5.6.4.1. Water Testing Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 5.7. Bioenergy & Agricultural Research
  • 5.7.1. Bioenergy & Agricultural Research Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 5.8. Cosmetics and Personal Care Applications
  • 5.8.1. Cosmetics and Personal Care Applications Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 6. Microbiology & Bacterial Culture Media Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Western Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Eastern Europe
  • 6.5.1. Poland
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Poland market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Hungary
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Hungary market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Czech Republic
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Czech Republic market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Bulgaria
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Bulgaria market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. India
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Australia
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. South East Asia
  • 6.7.1. Thailand
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Vietnam
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Vietnam market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. Indonesia
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. Indonesia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Singapore
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Position Analysis, 2024
• 7.4. Company Profiles/Listing
  • 7.4.1. Merck KGaA
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. bioMerieux SA
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. HiMedia Laboratories
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Thermo Fisher Scientific Inc.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. BD
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Solabia Group (Biokar diagnostics)
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Titan Biotech Ltd.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. CONDALAB
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Neogen Corporation
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Bio-Rad Laboratories, Inc.
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. SHIMADZU
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives
  • 7.4.12. Hardy Diagnostics
    • 7.4.12.1. Company overview
    • 7.4.12.2. Financial performance
    • 7.4.12.3. Product benchmarking
    • 7.4.12.4. Strategic initiatives
  • 7.4.13. R-Biopharm AG
    • 7.4.13.1. Company overview
    • 7.4.13.2. Financial performance
    • 7.4.13.3. Product benchmarking
    • 7.4.13.4. Strategic initiatives
  • 7.4.14. Alpha Teknova, Inc.
    • 7.4.14.1. Company overview
    • 7.4.14.2. Financial performance
    • 7.4.14.3. Product benchmarking
    • 7.4.14.4. Strategic initiatives
  • 7.4.15. MP Biomedicals
    • 7.4.15.1. Company overview
    • 7.4.15.2. Financial performance
    • 7.4.15.3. Product benchmarking
    • 7.4.15.4. Strategic initiatives
  • 7.4.16. Micromaster Laboratories Pvt. Ltd.
    • 7.4.16.1. Company overview
    • 7.4.16.2. Financial performance
    • 7.4.16.3. Product benchmarking
    • 7.4.16.4. Strategic initiatives
  • 7.4.17. ELEX Biological Products (Shanghai) Co., Ltd.
    • 7.4.17.1. Company overview
    • 7.4.17.2. Financial performance
    • 7.4.17.3. Product benchmarking
    • 7.4.17.4. Strategic initiatives
  • 7.4.18. Eiken Chemical Co., Ltd.
    • 7.4.18.1. Company overview
    • 7.4.18.2. Financial performance
    • 7.4.18.3. Product benchmarking
    • 7.4.18.4. Strategic initiatives